{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099355","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.191724+00:00","generated_at":"2026-05-15T16:51:03.707431+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track","bullets":["Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.","Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.","Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.","Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.","Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099355","json":"https://secwatch.observer/filing/0001193125-26-099355.json","markdown":"https://secwatch.observer/filing/0001193125-26-099355.md","text":"https://secwatch.observer/filing/0001193125-26-099355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/0001193125-26-099355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/cgem-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:51:03.707431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}